CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR PROPHYLAXIS AND THERAPY OF EBV

临床试验：用于预防和治疗 EBV 的自体 EBV 特异性 CTLS

• 批准号: 7950584
• 负责人: HELEN E HESLOP
• 金额: $ 0.03万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950584
• 关键词: Antiviral Agents; Autologous; Cell Line; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic T-Lymphocytes; Funding; Grant; Individual; Institution; Organ Transplantation; Patients; Prophylactic treatment; Protocols documentation; Research; Research Personnel; Resources; Safety; Solid; Source; United States National Institutes of Health; intravenous injection

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this protocol are: 1. Generate autologous, EBV-specific, cytotoxic T cell lines (CTLs) from individuals receiving or having received a solid organ transplant (SOT). 2. Administer autologous, EBV-specific CTLs to patients, to determine the safety of intravenous injections in these individuals. 3. Evaluate the antiviral and immunological efficacy of the infused CTLs.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该协议的目标是： 1。从接受或接受固体器官移植（SOT）的个体中产生自体，EBV特异性的细胞毒性T细胞系（CTL）。 2。对患者进行自体内EBV特异性CTL，以确定这些个体静脉注射的安全性。 3。评估注入CTL的抗病毒和免疫学功效。